Skip to main content
. Author manuscript; available in PMC: 2019 Dec 25.
Published in final edited form as: J Am Coll Cardiol. 2018 Dec 25;72(25):3246–3254. doi: 10.1016/j.jacc.2018.09.076

Figure 2. Cumulative incidence of HF, CVD, and mortality by classes of longitudinal change in galectin-3.

Figure 2.

Persistently high levels of Gal-3 were associated with significantly higher risk of incident HF (A), incident CVD (B), and all-cause mortality (C). High-high, low-high, high-low, and low-low represent classes of change in Gal-3 between the earlier exam and the later exam using the clinical cut-off of 17.8 ng/ml. CVD = cardiovascular disease, HF = heart failure.